JP2020517707A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517707A5 JP2020517707A5 JP2019558443A JP2019558443A JP2020517707A5 JP 2020517707 A5 JP2020517707 A5 JP 2020517707A5 JP 2019558443 A JP2019558443 A JP 2019558443A JP 2019558443 A JP2019558443 A JP 2019558443A JP 2020517707 A5 JP2020517707 A5 JP 2020517707A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmaceutically acceptable
- treatment
- item
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 10
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000011519 second-line treatment Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 239000003981 vehicle Substances 0.000 claims 2
- 238000000034 method Methods 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Chemical group 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 229910052717 sulfur Chemical group 0.000 description 6
- 239000011593 sulfur Chemical group 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 229920006395 saturated elastomer Chemical group 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- -1 1H-pyrrolill Chemical group 0.000 description 1
- VZWOXDYRBDIHMA-UHFFFAOYSA-N 2-methyl-1,3-thiazole Chemical compound CC1=NC=CS1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 1
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 206010072930 Mucolipidosis type IV Diseases 0.000 description 1
- 102100026502 Mucolipin-1 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762490280P | 2017-04-26 | 2017-04-26 | |
| US62/490,280 | 2017-04-26 | ||
| PCT/US2018/029288 WO2018200625A1 (en) | 2017-04-26 | 2018-04-25 | Modulators of sestrin-gator2 interaction and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517707A JP2020517707A (ja) | 2020-06-18 |
| JP2020517707A5 true JP2020517707A5 (https=) | 2021-07-29 |
| JP7179015B2 JP7179015B2 (ja) | 2022-11-28 |
Family
ID=63920059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558443A Active JP7179015B2 (ja) | 2017-04-26 | 2018-04-25 | Ｓｅｓｔｒｉｎ－ＧＡＴＯＲ２相互座用のモジュレーターおよびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10912750B2 (https=) |
| EP (2) | EP4556069A3 (https=) |
| JP (1) | JP7179015B2 (https=) |
| CN (2) | CN110809467B (https=) |
| AU (2) | AU2018258355B2 (https=) |
| CA (1) | CA3061611A1 (https=) |
| ES (1) | ES3040534T3 (https=) |
| PL (1) | PL3615019T3 (https=) |
| TW (1) | TWI776886B (https=) |
| WO (1) | WO2018200625A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016342027B2 (en) | 2015-10-23 | 2021-05-13 | Navitor Pharmaceuticals, Inc. | Modulators of Sestrin-GATOR2 interaction and uses thereof |
| PL3615019T3 (pl) | 2017-04-26 | 2026-01-19 | Navitor Pharmaceuticals, Inc. | Modulator interakcji sestryna-gator2 do zastosowania w leczeniu depresji opornej na leczenie |
| EP3870158A4 (en) | 2018-10-24 | 2022-08-10 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| JP7189368B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４ベータ７インテグリンの阻害のための化合物 |
| FI3873884T3 (fi) | 2018-10-30 | 2025-02-24 | Gilead Sciences Inc | 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa |
| ES3013256T3 (en) | 2018-10-30 | 2025-04-11 | Gilead Sciences Inc | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| EP3873605B1 (en) | 2018-10-30 | 2024-10-23 | Gilead Sciences, Inc. | Compounds for inhibition of alpha4beta7 integrin |
| CN111689993B (zh) * | 2019-03-11 | 2023-04-14 | 凯特立斯（深圳）科技有限公司 | 一种新的含硼类佐米药物关键中间体手性α-氨基硼酸酯的制备方法 |
| WO2021030438A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| US11723890B2 (en) * | 2019-11-01 | 2023-08-15 | Navitor Pharmaceuticals, Inc. | Methods of treatment using an mTORC1 modulator |
| CN113876784B (zh) * | 2021-09-27 | 2023-07-21 | 潍坊博创国际生物医药研究院 | 硼代亮氨酸类化合物的新用途 |
| CN115927459A (zh) * | 2022-07-19 | 2023-04-07 | 华南农业大学 | 猪ctns基因在促进动物骨骼肌生长中的应用 |
| AU2023374029A1 (en) * | 2022-11-01 | 2025-05-08 | Navitor Pharmaceuticals, Inc. | MODULATORS OF mTORC1 ACTIVITY AND USES THEREOF |
| WO2026085331A1 (en) * | 2024-10-16 | 2026-04-23 | Navitor Pharmaceuticals, Inc. | Mefluleucin for use in the treatment of suicidal ideations associated with depression |
| CN120993707B (zh) * | 2025-08-18 | 2026-02-10 | 衡水海宏环保设备制造有限公司 | 一种滤饼成型动态压控智能调控方法 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110368A (en) | 1972-07-24 | 1978-08-29 | American Cyanamid Company | Hydro substituted prostanoic acids and esters |
| US4346110A (en) * | 1981-06-01 | 1982-08-24 | Merrell Toraude Et Compagnie | Method for treating depression |
| JPS61149964A (ja) | 1984-12-25 | 1986-07-08 | Canon Inc | 電子写真感光体 |
| US4670196A (en) | 1985-09-05 | 1987-06-02 | Norton Company | Tower packing element |
| DE3765646D1 (de) | 1986-01-24 | 1990-11-29 | Toray Industries | 2,5,6,7-tetranor-4,8-inter-m-phenylen-pgi2-derivate. |
| GB8827885D0 (en) | 1988-11-30 | 1989-01-05 | Wellcome Found | Novel heterocyclic pesticidal compounds |
| US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
| DE19623142A1 (de) | 1996-06-10 | 1997-12-11 | Huels Chemische Werke Ag | Enantiomerenangereicherte, durch einen tertiären Kohlenwasserstoffrest substituierte Malonsäuremonoester sowie deren Herstellung |
| BR9713182A (pt) | 1996-08-28 | 1999-11-03 | Procter & Gamble | Amidas de ácido fosfìnico como inibidores de metalo protease de matriz |
| US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
| US6458781B1 (en) | 1998-04-27 | 2002-10-01 | David Thomas Connor | Substituted diarylalkyl amides as calcium channel antagonists |
| AU6342099A (en) | 1998-11-04 | 2000-05-22 | Montell Technology Company B.V. | Components and catalysts for the polymerization of olefins |
| US6329546B1 (en) | 1999-01-12 | 2001-12-11 | Laboratory Of Molecular Biophotonics | Caged amino acids |
| US20030203900A1 (en) | 1999-05-18 | 2003-10-30 | Martin Quibell | Cysteine protease inhibitors |
| RS50352B (sr) | 1999-06-10 | 2009-11-10 | Warner-Lambert Company Llc., | Monosupstituisane 3-propil gama-aminobuterne kiseline |
| WO2002043507A2 (en) * | 2000-11-30 | 2002-06-06 | The Health Research Institute | Nutrient supplements and methods for treating autism and for preventing the onset of autism |
| JP5076257B2 (ja) | 2001-02-01 | 2012-11-21 | 旭硝子株式会社 | 撥水性組成物、表面処理された基材、その製造方法および輸送機器用物品 |
| DE60217322T2 (de) | 2001-04-27 | 2007-10-04 | Zenyaku Kogyo K.K. | Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| PT1536827E (pt) | 2002-08-14 | 2009-03-20 | Silence Therapeutics Ag | Utilização de proteína cinase n beta |
| US6787664B2 (en) | 2002-09-17 | 2004-09-07 | Warner-Lambert Company Llc | Process for preparing single enantiomers of 5,5,5,5′,5′,5′-hexafluoroleucine and protected analogs |
| AU2002953255A0 (en) | 2002-12-11 | 2003-01-02 | Cytopia Research Pty Ltd | Protein kinase inhibitors |
| AU2004228668B2 (en) | 2003-04-03 | 2011-10-27 | Park Funding, Llc | PI-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| EP1692153A4 (en) | 2003-07-03 | 2007-03-21 | Univ Pennsylvania | INHIBITION OF EXPRESSION OF SYK-KINASE |
| WO2005113556A1 (en) | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| US20070212428A1 (en) * | 2004-06-04 | 2007-09-13 | Mood Management Sciences, Inc. | Methods and compositions for treating mood disorder |
| DE102004053407A1 (de) | 2004-11-05 | 2006-05-11 | Bayer Healthcare Ag | Acylierte Nonadepsipeptide II |
| AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| EP1853552A2 (en) | 2005-02-18 | 2007-11-14 | Innodia Inc. | Diastereoisomers of 4-hydroxyisoleucine and uses thereof |
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| US7989622B2 (en) | 2005-10-07 | 2011-08-02 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2007129161A2 (en) | 2006-04-26 | 2007-11-15 | F. Hoffmann-La Roche Ag | Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor |
| JP2010501566A (ja) | 2006-08-21 | 2010-01-21 | プレクサ ファーマシューティカルズ， インコーポレイテッド | 中枢神経系障害の治療において使用するための多伝達物質トランスポータ阻害剤 |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| EP2069339B1 (en) | 2006-09-25 | 2011-05-18 | Wockhardt Research Centre | Substituted piperidinophenyl oxazolidinones |
| TWI397418B (zh) | 2006-10-10 | 2013-06-01 | Otsuka Pharma Co Ltd | 抗憂鬱劑 |
| CA2666310C (en) | 2006-10-20 | 2012-07-31 | Merck & Co., Inc. | Substituted imidazoles as bombesin receptor subtype-3 modulators |
| KR101566840B1 (ko) | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| TW200902019A (en) | 2007-04-26 | 2009-01-16 | Ono Pharmaceutical Co | Dicyclic heterocyclic compound |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| US8431608B2 (en) | 2007-08-17 | 2013-04-30 | Icagen Inc. | Heterocycles as potassium channel modulators |
| CN101903349B (zh) | 2007-08-27 | 2014-01-08 | Abbvie德国有限责任两合公司 | 4-(4-吡啶基)-苯甲酰胺及其作为rock活性调节剂的应用 |
| HUE029767T2 (en) | 2008-03-11 | 2017-04-28 | Incyte Holdings Corp | JAK inhibitor azetidine and cyclobutane derivatives |
| WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| EP2350053B1 (en) * | 2008-10-17 | 2013-12-11 | Whitehead Institute For Biomedical Research | Modulators of MTOR Complexes |
| EP2443128B1 (en) | 2009-06-19 | 2017-12-20 | LEK Pharmaceuticals d.d. | New synthetic route for the preparation of alpha-amino boronic esters |
| WO2011012283A1 (en) * | 2009-07-30 | 2011-02-03 | University Of Zurich | Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event |
| PH12012501535A1 (en) | 2010-01-29 | 2012-10-22 | Boehringer Ingelheim Int | Substituted naphthyridines and their use as syk kinase inhibitors |
| ES2689103T3 (es) * | 2010-06-30 | 2018-11-08 | Fujifilm Corporation | Nuevo derivado de nicotinamida o sal del mismo |
| CN102464701B (zh) | 2010-11-08 | 2015-10-21 | 上海医药工业研究院 | 一类新型化合物、其制备方法及用途 |
| WO2012076063A1 (en) | 2010-12-10 | 2012-06-14 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| WO2012113847A1 (en) | 2011-02-25 | 2012-08-30 | Lonza Ltd | Branched linker for protein drug conjugates |
| US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| EP2763975B1 (en) | 2011-10-05 | 2016-04-06 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| EP2589383A1 (en) * | 2011-11-06 | 2013-05-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | FKBP subtype-specific rapamycin analogue for use in treatment of diseases |
| WO2013142229A1 (en) | 2012-03-19 | 2013-09-26 | President And Fellows Of Harvard College | Designing novel peptides for inducing fibronectin matrix assembly |
| EP2880014B1 (en) | 2012-08-06 | 2017-05-17 | Pitney Pharmaceuticals Pty Limited | Compounds for the treatment of mtor pathway related diseases |
| WO2014127052A1 (en) | 2013-02-13 | 2014-08-21 | Zondlo Neal | Perfluoro-tert-butyl hydroxyproline |
| WO2014145852A2 (en) | 2013-03-15 | 2014-09-18 | Knopp Biosciences Llc | Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators |
| US20160129030A1 (en) | 2013-06-14 | 2016-05-12 | The Brigham And Women's Hospital, Inc. | Treatment of mtor hyperactive related diseases and disorders |
| EP3191116B1 (en) * | 2014-09-12 | 2020-11-25 | The Whitehead Institute for Biomedical Research | Methods of identifying modulators of sestrin-gator2 interaction and use of same to modulate mtorc1 |
| AU2016342027B2 (en) * | 2015-10-23 | 2021-05-13 | Navitor Pharmaceuticals, Inc. | Modulators of Sestrin-GATOR2 interaction and uses thereof |
| US20180327364A1 (en) | 2015-11-13 | 2018-11-15 | Brandeis University | Mtor inhibitors and methods of use thereof |
| EP3445451B1 (en) | 2016-04-21 | 2021-08-18 | Baylor College of Medicine | Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction |
| PL3615019T3 (pl) | 2017-04-26 | 2026-01-19 | Navitor Pharmaceuticals, Inc. | Modulator interakcji sestryna-gator2 do zastosowania w leczeniu depresji opornej na leczenie |
| KR20250167147A (ko) | 2018-02-08 | 2025-11-28 | 오비드 테라퓨틱스 인크. | 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도 |
| EP3870158A4 (en) | 2018-10-24 | 2022-08-10 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| US10926803B2 (en) | 2019-07-17 | 2021-02-23 | GM Global Technology Operations LLC | Four rail front crush structure with load dissemination into eight element support structure |
| US11723890B2 (en) | 2019-11-01 | 2023-08-15 | Navitor Pharmaceuticals, Inc. | Methods of treatment using an mTORC1 modulator |
| JP6689441B1 (ja) | 2019-11-01 | 2020-04-28 | エヌ・ティ・ティ・コミュニケーションズ株式会社 | 電子マネー管理システムおよび電子マネー管理方法 |
-
2018
- 2018-04-25 PL PL18791427.0T patent/PL3615019T3/pl unknown
- 2018-04-25 ES ES18791427T patent/ES3040534T3/es active Active
- 2018-04-25 JP JP2019558443A patent/JP7179015B2/ja active Active
- 2018-04-25 EP EP25169183.8A patent/EP4556069A3/en active Pending
- 2018-04-25 CN CN201880039788.3A patent/CN110809467B/zh active Active
- 2018-04-25 CN CN202310282338.XA patent/CN116370448B/zh active Active
- 2018-04-25 WO PCT/US2018/029288 patent/WO2018200625A1/en not_active Ceased
- 2018-04-25 CA CA3061611A patent/CA3061611A1/en active Pending
- 2018-04-25 US US15/962,123 patent/US10912750B2/en active Active
- 2018-04-25 TW TW107114086A patent/TWI776886B/zh active
- 2018-04-25 EP EP18791427.0A patent/EP3615019B1/en active Active
- 2018-04-25 AU AU2018258355A patent/AU2018258355B2/en active Active
-
2020
- 2020-11-30 US US17/106,584 patent/US11679090B2/en active Active
-
2023
- 2023-05-01 US US18/141,834 patent/US12427130B2/en active Active
-
2024
- 2024-08-30 AU AU2024216489A patent/AU2024216489A1/en active Pending
-
2025
- 2025-08-20 US US19/304,835 patent/US20260034084A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517707A5 (https=) | ||
| JP2018538248A5 (https=) | ||
| AU2013249790B2 (en) | Ring constrained analogs as Arginase inhibitors | |
| JP2013532652A5 (https=) | ||
| JP2021527126A5 (https=) | ||
| JP2019520344A5 (https=) | ||
| JP2020507589A5 (https=) | ||
| JP2006505543A5 (https=) | ||
| JP2010506854A5 (https=) | ||
| JP2011529964A5 (https=) | ||
| JP2019529444A5 (https=) | ||
| JP2008535903A5 (https=) | ||
| JP2007527919A5 (https=) | ||
| JP2012530779A5 (https=) | ||
| JP2018524304A5 (https=) | ||
| RU2018127728A (ru) | Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич | |
| JP2020533352A5 (https=) | ||
| JP2021504314A5 (https=) | ||
| RU2010119458A (ru) | 1,3,5-тризамещенное производное триазола | |
| JP2022508953A (ja) | Ｈｂｖの処置のための５員のヘテロアリールカルボキサミド化合物 | |
| JP2015536997A5 (https=) | ||
| JP2018527301A5 (ja) | アジリジン含有ｄｎａアルキル化剤 | |
| JP2024516033A5 (https=) | ||
| RU2008107733A (ru) | Ингибиторы gsk-3 | |
| JP2020128426A5 (https=) |